Bayer’s Nubeqa Secures Third FDA Approval, Expanding Prostate Cancer Treatment Landscape Bayer has announced that the U.S. Food and Drug Administration (FDA) has granted approval for a third indication of its oral androgen receptor inhibitor, Nubeqa™ (darolutamide). This latest approval…
Eli Lilly Presents Promising Phase 1 Data for Investigational FRα-Targeting ADC in Platinum-Resistant Ovarian Cancer at ASCO 2025 Eli Lilly and Company has announced encouraging new Phase 1 clinical data for its investigational folate receptor alpha (FRα) targeting antibody-drug conjugate…
Protagonist Therapeutics and Takeda Reveal Comprehensive Phase 3 VERIFY Study Results for Rusfertide in Polycythemia Vera at ASCO 2025 Protagonist Therapeutics,and Takeda Pharmaceutical Company Limited have announced detailed findings from the Phase 3 VERIFY clinical trial evaluating rusfertide, an investigational…
Merck’s Zilovertamab Vedotin in Combination With R-GemOx Shows Promising Efficacy in Relapsed/Refractory DLBCL Patients: Phase 2 Results from waveLINE-003 Trial Presented at ASCO 2025 Merck, known as MSD outside the United States and Canada, has unveiled encouraging new clinical data…
Global Unity, Historic Milestones: 78th World Health Assembly Concludes with Ambitious Health Agenda The Seventy-eighth World Health Assembly (WHA78), the flagship decision-making forum of the World Health Organization (WHO), drew to a close on May 27, 2025, marking what many…
Elanco Names Robert VanHimbergen as New CFO, Succeeding Todd Young in Strategic Leadership Transition Elanco Animal Health Incorporated has officially announced the appointment of Robert (Bob) VanHimbergen as Executive Vice President and Chief Financial Officer (CFO), effective July 7, 2025.…
AskBio Publishes Complete Phase 1b Trial Results of AB-1005 Gene Therapy for Parkinson’s Disease in Leading Neurology Journal Asklepios BioPharmaceutical, Inc. (AskBio), a pioneering gene therapy company that operates as a wholly owned, independent subsidiary of the global pharmaceutical giant…
Novartis Launches Tender Offer to Acquire Regulus Therapeutics in $7 Per Share Deal, with Potential Bonus Payout Linked to Regulatory Milestone In a strategic move that underscores its continued investment in innovative biotechnology, Novartis announced today that its wholly owned…
WHO Launches Landmark Guideline to Bridge Global Gaps in Access to Controlled Medicines In a bold step toward improving global health equity, the World Health Organization (WHO) unveiled a new guideline aimed at helping countries strike a critical balance between…
Eisai’s Lemborexant (DAYVIGO®) Receives Regulatory Approval in China for the Treatment of Insomnia Eisai Co., Ltd., a leading global pharmaceutical company headquartered in Tokyo and led by CEO Haruo Naito, announced a significant milestone in its global expansion strategy with…
Cullinan Therapeutics and Taiho Highlight Promising Phase 2b Results of Zipalertinib in Advanced EGFR ex20ins NSCLC at ASCO 2025 Cullinan Therapeutics,in collaboration with Taiho Pharmaceutical Co., Ltd., and its U.S. affiliate Taiho Oncology, Inc., has announced encouraging new results from…
Bayer Launches Centafore Imaging Core Lab to Revolutionize Clinical Trial Imaging and SaMD Development Bayer, a global leader in healthcare and life sciences, today officially announced the launch of its Imaging Core Lab under the new brand name Centafore™. This…
